ASCOT-LLA and the primary prevention of coronary artery disease in hypertensive patients

Current Atherosclerosis Reports

Volumn 6, Issue 5, 2004, Pages 353-358

  Nambi, Vijay ^a   Ballantyne, Christie M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; SIMVASTATIN;

CHOLESTEROL BLOOD LEVEL; CLINICAL STUDY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG MECHANISM; EVIDENCE BASED MEDICINE; HEALTH PROGRAM; HUMAN; HYPERTENSION; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PRIMARY PREVENTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; UNITED STATES;

EID: 5444245839     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-004-0046-1     Document Type: Review

References (15)

1. Expert Panel: Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med 1988, 148: 36-69.
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
3. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22.
4. Sever PS, Dahlöf B, Poulter NR, et al., for the ASCOT Investigators: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361: 1149-1158.
5. Sever PS, Dahlöf B, Poulter NR, et al., for the ASCOT Investigators: Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. J Hypertens 2001, 19:1139-1147.
6. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002, 288:2998-3007.
7. Sacks FM, Tonkin AM, Shepherd I, et al.: Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation 2000, 102:1893-1900.
8. Jones PH, Davidson MH, Stein EA, et al., for the STELLAR Study Group: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003, 92: 152-160.
9. Nelson K, Norris K, Mangione CM: Disparities in the diagnosis and pharmacologic treatment of high serum cholesterol by race and ethnicity: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2002, 162:929-935.
10. Sharrett AR, Ballantyne CM, Coady SA, et al.: Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001, 104:1108-1113.
11. Stein DT, Devaraj S, Balis D, et al.: Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2001, 21:2026-2031.
12. Schaefer EJ, McNamara JR, Tayler T, et al.: Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects. Am J Cardiol 2002, 90:689-696.
13. Tsimihodimos V, Karabina SA, Tambaki AP, et al.: Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler Thromb Vasc Biol 2002, 22:306-311.
14. Nissen SE, Tuzcu EM, Schoenhagen P, et al., for the REVERSAL Investigators: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004, 291:1071-1080.
15. Cannon CP, Braunwald E, McCabe CH, et al., for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators: Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495-1504.